Multiple Manufacturers

OGIVRI

Manufacturer:

Multiple Manufacturers

Ogivri HCPCS:

Q5114

HCPCS Code Descriptor:

Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg

Category:

Q Code

Ogivri NDCs:

67457-0847-44, 83257-0004-12, 67457-0991-15, 83257-0001-11

Primary Type:

Oncology Biosimilar

Generic/Specialty Status:

Multi-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

67457-0847-44, 67457-0991-15

About Ogivri:

OGIVRI is an Oncology Biosimilar drug manufactured by Mylan and administered via the Intravenous route of administration. The Q Code: Q5114 is aligned to the drug OGIVRI.

Ogivri (trastuzumab) is a cancer drug that targets the HER2 protein in cancer cells. This medication can be used to treat specific types of breast and stomach cancers. Ogivri can be used in combination with other cancer medications. Ogivri is manufactured by Mylan instituitional and is biosimilar to the medication Herceptin (J9356). Ogivri has been aligned to the HCPCS code Q5114 since July 2019. Patient assistance programs for this medication can be found through Viatris Patient Assistance.

ACCESS PRICING AND MORE BY REGISTERING

Q5114 Added Date:

July 1, 2019

Q5114 Effective Date:

July 1, 2019

Q5114 Termination Date:

HCPCS Active

Ogivri billing and coding information can be found through Mylan at the link below:
Ogivri patient assistance information can be found through Viatris Patient Assistance Program at the URL: https://www.viatris.com/en-us/lm/united-states/patient-assistance-program
OGIVRI prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date.
Our team has not yet identified a source of side effects information for OGIVRI. Please check back in a few weeks.